Date: 2013-11-18
Type of information: Fundraising
Company: Ganymed Pharmaceuticals (Germany)
Investors: ATS Beteiligungsverwaltung GmbH (Germany), MIG Fond (Germany), FCPB Gany GmbH (Germany)
Amount: € 45 Million
Funding type: Series E financing round
Planned used: Ganymed will use the proceeds to accelerate the clinical development of its lead program IMAB362, including completion of the ongoing Phase IIa and IIb clinical trials in gastroesophageal cancer, and to prepare this first-in-class antibody for a Phase III study. Concomitantly, the Company will clinically validate its IVD test, CLAUDETECT™18.2, as a predictive companion diagnostic test to IMAB362. The financing will also allow Ganymed to conduct a Phase I/II clinical study of IMAB027 in ovarian cancer and develop a companion diagnostic test for this antibody.
Others: * On November 18, 2013, Ganymed Pharmaceuticals AG, a biopharmaceutical company developing highly selective Ideal Monoclonal Antibodies (IMABs) for the treatment of cancer, has announced the completion of a €45 million Series E financing from existing investors ATS Beteiligungsverwaltung GmbH, MIG Fond, and FCPB Gany GmbH.
Therapeutic area: Cancer - Oncology
